Bottom line
SBHIX vs IBB: the short answer
SBHIX (Health & Biotechnology Portfolio) and IBB (iShares Biotechnology ETF) are both mutual funds.
But IBB is far broader, holding 254 positions to 29 for SBHIX, so beyond the top names it adds exposure SBHIX doesn't have.
IBB is cheaper at 0.44% vs 2.6% — a difference of $216 a year per $10,000 invested.
Over five years, SBHIX returned +4.7% a year vs +2.5% for IBB (reporting dates differ).
Updated Nov 19, 2026
SBHIX vs IBB side by side
| SBHIX | IBB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Saratoga Advantage | iShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.6% | 0.44% |
| Annual cost per $10k | $260 | $44 |
| 10-yr cost on $10k (prospectus) | $2,934 | $555 |
| Max front load | 0% | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +0.7% | +28.0% |
| 5-yr return (annualized) | +4.7% | +2.5% |
| 10-yr return (annualized) | +5.2% | +4.4% |
| Best quarter | +15.0% | +26.8% |
| Worst quarter | −13.0% | −22.9% |
| Net assets (fund) | $10.5M | $5.9B |
| Number of holdings | 29 | 254 |
| Portfolio turnover | 22% | 27% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SBHIX | IBB | Difference |
|---|---|---|---|
| 2024 | +0.7% | −2.4% | +3.1% |
| 2023 | +0.0% | +3.6% | −3.6% |
| 2022 | +2.4% | −13.6% | +16.0% |
| 2021 | +17.2% | +1.0% | +16.2% |
| 2020 | +4.0% | +25.9% | −21.9% |
| 2019 | +16.6% | +24.8% | −8.1% |
| 2018 | −5.0% | −9.1% | +4.1% |
| 2017 | +12.4% | +21.2% | −8.8% |
| 2016 | −1.5% | −21.5% | +20.0% |
| 2015 | +7.3% | +11.5% | −4.2% |
Source: Fund prospectus bar charts
Holdings overlap
8 of SBHIX's top 25 holdings also appear in IBB's top 25.
| Holding | SBHIX | IBB |
|---|---|---|
| United Therapeutics Corp | 6.17% | 1.82% |
| Amgen Inc | 5.04% | 7.50% |
| Exelixis Inc | 4.55% | 1.07% |
| Gilead Sciences Inc | 3.94% | 7.52% |
| Regeneron Pharmaceuticals Inc | 3.93% | 5.70% |
| Medpace Holdings Inc | 3.37% | 1.16% |
| Vertex Pharmaceuticals Inc | 3.36% | 7.66% |
| Incyte Corp | 2.89% | 1.62% |
Source: SEC Form N-PORT
SBHIX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FAQ
What is the difference between SBHIX and IBB?
Which is cheaper, SBHIX or IBB?
Should I own both SBHIX and IBB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.